Cryospray Ablation Research Articles

Cryospray Ablation of Early Stage Esophageal Cancer

AdCa-adenocarcinoma, SCC-squamous cell carcinoma, EMR-mucosal resection, chemo/xrt-combination chemotherapy/radiation therapy, LGD-low grade dysplasia, IM-intestinal metaplasia

Cryospray ablation (CSA) in the palliative treatment of squamous cell carcinoma of the esophagus

BackgroundEsophageal carcinoma is the ninth most prevalent cancer worldwide with squamous cell carcinoma (SCCA) and adenocarcinoma accounting for the vast majority of new cases (13,900 in 2003). Cure rates in the U.S. are less than 10%, similar to lung cancer. More than 50% of patients with esophageal carcinoma present with unresectable or metastatic disease, are not surgical candidates, or display disease progression despite the addition of neoadjuvant chemoradiotherapy to surgery. Need for improved palliation exits.Case presentationThis case describes a 73-year-old African American male who presented with recurrent squamous cell carcinoma (SCCA) of the esophagus who has a achieved complete remission for 24 months via endoscopic cryospray ablation.ConclusionEndoscopic cryo spray ablation warrants further investigation as a palliative treatment modality for esophageal cancer. This is the first reported case in the medical literature.